Orchid Pharma confirmed that its 7-ACA backward integration project is set to begin operations by March 2027. The company stated that commissioning and the first commercial batch are targeted for this timeline.

This update reinforces the strategic roadmap previously outlined, where the project aims to reach 80-100% utilization by the end of its first year. Management has indicated that 80% of the output is intended for in-house use, with the remaining 20% allocated for third-party sales. The capital expenditure for this initiative stands at ₹750 crore.

Financial Performance

The company reported a standalone net profit of ₹12 crore for Q1FY27, reversing a net loss of ₹3 crore in Q1FY26. Revenue from operations rose 15% to ₹304 crore from ₹263 crore in the corresponding period last year.

What the Numbers Show

The simultaneous rise in revenue and the transition from a net loss to a net profit suggests effective cost structure management. The revenue increase of 15% coupled with a 150% surge in EBITDA underscores financial recovery. Notably, the EBITDA margin expanded from 3% to 8%, indicating improving operating leverage as the merged entity optimizes its integrated cephalosporin platform.

Operational and Strategic Updates

Management highlighted that FY26 was challenging for the cephalosporin business, with combined revenue falling to ₹1,233 crore from ₹1,398 crore in FY25 due to volume and pricing pressures. Gross margins moderated by approximately 4 percentage points to 32% in FY26 compared to 36% in FY25. However, combined employee and other operating expenses remained broadly flat at ₹353 crore in both years.

In Q1FY27, gross margins improved by approximately 3 percentage points to 33%. The Antimicrobial Stewardship (AMS) business continues to be managed with financial discipline, with quarterly EBITDA drag reducing significantly. AMS revenue was approximately ₹5 crore in the quarter, with an EBITDA loss of around ₹50 lakh.

Pipeline and Project Timelines

Orchid Pharma provided updates on key strategic projects:

• Exblifep: In Europe, volumes grew by approximately 300% in Q3FY26, 170% in Q4FY26, and 50% in Q1FY27. Registration in South Africa is complete, with coverage across GCC markets. Discussions are advanced for South America, Mexico, Philippines, Thailand, Morocco, and Australia. The estimated 10-year value of the licensing arrangement in Russia is approximately $178 million.
• Cefiderocol: The project remains on schedule for commissioning by December 2026. Validation and initial batches are targeted for January to March 2027. Commercial launch depends on DCGI approval, potentially via a trial waiver precedent set by Cefepime-Enmetazobactam. GARDP has floated a global RFP for market access in 135 countries.
• 7-ACA Project: Commissioning and the first commercial batch are targeted by March 2027. This backward integration project aims to reach 80-100% utilization by the end of the first year, with 80% intended for in-house use and 20% for third-party sales. The capex for this project is ₹750 crore.

Orchid Pharma has uploaded the audio recording of its quarterly earnings call, which was held on August 21, 2026. The session discussed the company's unaudited limited reviewed financial results for the first quarter of FY27, ended June 30, 2026.

The call took place at 3:00 pm IST and was hosted by Systematix Institutional Equities. Management provided insights into operational and financial performance for the period.

Management Participation

Key executives represented Orchid Pharma during the session:

• Manish Dhanuka, Managing Director
• Mridul Dhanuka, Whole Time Director
• Sunil Kumar Gupta, Chief Financial Officer

Regulatory Disclosure

The intimation was issued pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. It references SEBI Master Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

Kapil Dayya, Company Secretary and Compliance Officer, signed the disclosure. The information is available on the company's website at www.orchidpharma.com .

Audio Recording Access

Investors and analysts can access the audio recording via the link provided on the company's website. The call was conducted as an audio conference; no video recording is available.

Dial-In Details

For reference, the dial-in numbers used during the call are listed below: